<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:media="http://search.yahoo.com/mrss/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>GLP-1 weight loss Archives - The Daily Update</title>
	<atom:link href="https://thedailyupdate.co/tag/glp-1-weight-loss/feed/" rel="self" type="application/rss+xml" />
	<link>https://thedailyupdate.co/tag/glp-1-weight-loss/</link>
	<description>Stay ahead with daily news, insights, and trends that matter</description>
	<lastBuildDate>Wed, 13 May 2026 10:02:19 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.5</generator>

<image>
	<url>https://thedailyupdate.co/wp-content/uploads/2026/03/cropped-thedailyupdate_logo-32x32.png</url>
	<title>GLP-1 weight loss Archives - The Daily Update</title>
	<link>https://thedailyupdate.co/tag/glp-1-weight-loss/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Daily Pill Could Help Millions Keep Weight Off After Stopping Obesity Injections</title>
		<link>https://thedailyupdate.co/2026/05/13/daily-pill-could-help-millions-keep-weight-off-aft/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Wed, 13 May 2026 10:02:19 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[GLP-1 weight loss]]></category>
		<category><![CDATA[obesity treatment]]></category>
		<category><![CDATA[orforglipron]]></category>
		<guid isPermaLink="false">https://thedailyupdate.co/?p=66037</guid>

					<description><![CDATA[<p>New Daily Pill Offers Hope for Long-Term Weight Management After Injection Therapy A new daily pill could help people maintain their weight loss after stopping obesity injections. The drug, called orforglipron, has shown promising results in a landmark clinical trial. Researchers say it offers an effective and affordable alternative to injectable treatments. The findings have [&#8230;]</p>
<p>The post <a href="https://thedailyupdate.co/2026/05/13/daily-pill-could-help-millions-keep-weight-off-aft/">Daily Pill Could Help Millions Keep Weight Off After Stopping Obesity Injections</a> appeared first on <a href="https://thedailyupdate.co">The Daily Update</a>.</p>
]]></description>
										<content:encoded><![CDATA[<h2>New Daily Pill Offers Hope for Long-Term Weight Management After Injection Therapy</h2>
<p>A <strong>new daily pill</strong> could help people maintain their weight loss after stopping obesity injections. The drug, called <span style="color: #002954; font-weight: 600;">orforglipron</span>, has shown promising results in a landmark clinical trial. Researchers say it offers an <em>effective and affordable alternative</em> to injectable treatments. The findings have generated significant excitement across the global medical community.</p>
<p>The trial was <strong>presented at the European Congress on Obesity 2026</strong> in <span style="color: #002954; font-weight: 600;">Istanbul</span>. Researchers published the study in the journal <em>Nature Medicine</em>. <span style="color: #002954; font-weight: 600;">Eli Lilly</span>, the manufacturer of the weight-loss jab <span style="color: #002954; font-weight: 600;">Mounjaro</span>, funded the research. The study marks a potential turning point in long-term obesity care.</p>
<p>One major challenge with GLP-1 injections is the risk of regaining weight after stopping. Previous studies found that patients typically regained <span style="color: #FF3726; font-weight: 600;">two-thirds</span> of lost weight within a year of stopping jabs. This new trial suggests that <span style="color: #002954; font-weight: 600;">orforglipron</span> could significantly reduce that rebound. Experts say the implications for public health are substantial.</p>
<h3>What the Trial Found</h3>
<p>The trial followed <span style="color: #FF3726; font-weight: 600;">376 patients</span> in the <span style="color: #002954; font-weight: 600;">United States</span> who had already been on GLP-1 injections for <span style="color: #FF3726; font-weight: 600;">72 weeks</span>. Those patients had been using either <strong>tirzepatide</strong> (sold as <span style="color: #002954; font-weight: 600;">Mounjaro</span>) or <strong>semaglutide</strong> (sold as <span style="color: #002954; font-weight: 600;">Wegovy</span>). They then switched to either a daily <span style="color: #002954; font-weight: 600;">orforglipron</span> tablet or a placebo for one year. Neither group knew which treatment they received.</p>
<p>Among patients who had previously used <strong>tirzepatide</strong>, those on <span style="color: #002954; font-weight: 600;">orforglipron</span> maintained <span style="color: #FF3726; font-weight: 600;">74.7%</span> of their weight loss. The placebo group maintained only <span style="color: #FF3726; font-weight: 600;">49.2%</span> of their earlier loss. For former <strong>semaglutide</strong> users, the pill group kept <span style="color: #FF3726; font-weight: 600;">79.3%</span> of their weight off. The placebo group, by comparison, retained just <span style="color: #FF3726; font-weight: 600;">37.6%</span>.</p>
<p>Beyond weight retention, the drug also sustained other health improvements. Participants on <span style="color: #002954; font-weight: 600;">orforglipron</span> maintained better <strong>blood pressure</strong>, <strong>cholesterol</strong>, and <strong>blood sugar levels</strong>. These are critical markers for cardiovascular and metabolic health. Researchers highlighted these additional benefits as particularly meaningful.</p>
<h3>How the Drug Works</h3>
<p><span style="color: #002954; font-weight: 600;">Orforglipron</span> belongs to a class of drugs known as <strong>GLP-1 agonists</strong>. It works by lowering blood sugar levels and slowing food digestion. The drug also reduces appetite, helping patients feel full for longer. Crucially, patients take it as a once-daily tablet rather than an injection.</p>
<p>This oral format could make treatment far more accessible. Many patients find injections burdensome due to storage requirements, travel restrictions, and personal preference. <u>The availability of an oral option could open treatment to a much wider group.</u> Experts say this distinction matters greatly for long-term adherence.</p>
<p><span style="color: #002954; font-weight: 600;">Dr. Marie Spreckley</span>, research programme manager at the <span style="color: #002954; font-weight: 600;">University of Cambridge</span>, praised the study&#8217;s real-world relevance. She said the trial reflected a <em>&#8220;highly realistic clinical scenario.&#8221;</em> She noted that many patients avoid injectable therapy due to cost, convenience, or personal preference. A viable oral transition option could therefore reshape long-term obesity care pathways.</p>
<h3>Expert Reactions and Medical Context</h3>
<p><span style="color: #002954; font-weight: 600;">Dr. Louis Aronne</span>, director of the <span style="color: #002954; font-weight: 600;">Comprehensive Weight Control Center at Weill Cornell Medicine</span>, called the findings significant. He argued that physicians should treat obesity more like other chronic diseases. <em>&#8220;The beauty of treating obesity is you are treating all of these things,&#8221;</em> he said. He added that effective obesity treatment eliminates the need to separately address cardiovascular risk factors.</p>
<p>About <span style="color: #FF3726; font-weight: 600;">30%</span> of adults in the <span style="color: #002954; font-weight: 600;">United Kingdom</span> currently live with obesity. Those on <span style="color: #002954; font-weight: 600;">Wegovy</span> or <span style="color: #002954; font-weight: 600;">Mounjaro</span> take around <span style="color: #FF3726; font-weight: 600;">seven medications</span> for related health conditions on average. Treating obesity effectively could therefore reduce the overall medication burden. This has major implications for national health systems like the <span style="color: #002954; font-weight: 600;">NHS</span>.</p>
<p><span style="color: #CC0001; font-weight: 600;">However, researchers caution that more long-term data is still needed.</span> Scientists do not yet know how durable the effects will be beyond the one-year trial period. Some experts suggest patients may need to remain on treatment indefinitely. <span style="color: #002954; font-weight: 600;">Dr. Spreckley</span> stressed that obesity is a <em>chronic, relapsing condition</em> that demands sustained management.</p>
<h3>Cost and Availability</h3>
<p>One of orforglipron&#8217;s most attractive features is its lower manufacturing cost. The drug costs approximately <span style="color: #FF3726; font-weight: 600;">$149 per month</span> in the <span style="color: #002954; font-weight: 600;">United States</span> at the lowest dose. By contrast, some GLP-1 injections cost <span style="color: #FF3726; font-weight: 600;">over $1,000 per month</span> in the US. Experts describe <span style="color: #002954; font-weight: 600;">orforglipron</span> as <u>significantly cheaper to manufacture</u> than current injectable alternatives.</p>
<p>The <span style="color: #002954; font-weight: 600;">US Food and Drug Administration</span> approved <span style="color: #002954; font-weight: 600;">orforglipron</span> last month. The drug could soon launch in the <span style="color: #002954; font-weight: 600;">United Kingdom</span>, though its UK pricing remains unknown. The drug has not yet received a UK market license. Authorities have not yet confirmed a timeline for a decision.</p>
<p>Rival manufacturer <span style="color: #002954; font-weight: 600;">Novo Nordisk</span> also developed an oral version of its GLP-1 drug <span style="color: #002954; font-weight: 600;">Wegovy</span>. The <span style="color: #002954; font-weight: 600;">US</span> has already approved that product. A <span style="color: #002954; font-weight: 600;">UK</span> decision on the <span style="color: #002954; font-weight: 600;">Novo Nordisk</span> oral drug remains pending. Competition between the two manufacturers could further drive down prices.</p>
<h3>What This Means for Patients</h3>
<p>Side effects from <span style="color: #002954; font-weight: 600;">orforglipron</span> were common in the trial but mostly mild. Patients reported <strong>nausea</strong>, <strong>constipation</strong>, and <strong>diarrhea</strong> as the most frequent complaints. These side effects mirror those seen with injectable GLP-1 treatments. Most participants tolerated them without discontinuing the drug.</p>
<p>The pill format removes several barriers that injectable drugs create. Patients no longer need to refrigerate medication or manage needles. <u>Oral treatment also reduces anxiety for those uncomfortable with self-injection.</u> These practical advantages could improve real-world treatment completion rates significantly.</p>
<p>Researchers stress that <span style="color: #002954; font-weight: 600;">orforglipron</span> is not a cure for obesity. The drug treats a chronic condition that requires <strong>ongoing, long-term management</strong>. Scientists urge health systems to invest in sustained treatment pathways. A cheaper oral pill represents one important step in that larger effort.</p>
<p>The post <a href="https://thedailyupdate.co/2026/05/13/daily-pill-could-help-millions-keep-weight-off-aft/">Daily Pill Could Help Millions Keep Weight Off After Stopping Obesity Injections</a> appeared first on <a href="https://thedailyupdate.co">The Daily Update</a>.</p>
]]></content:encoded>
					
		
		
		<media:content url="https://thedailyupdate.co/wp-content/uploads/2026/05/website_2026-05_hero_daily-pill-could-help-millions-keep-weight-off-aft_3a3cd746.jpg" medium="image"></media:content>
	</item>
	</channel>
</rss>
